Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 7/20 | 0.49 |
| ▸ | MMP9 | P14780 | 4/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881651 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTRXFP1POLBMMP2 | |
| SCHEMBL5878266 | 0.86 | ITGB3 (0.57) | ALDH1A1MAPTRXFP1ATML3MBTL1 | |
| SCHEMBL5878278 | 0.86 | ITGB3 (0.57) | ALDH1A1MAPTRXFP1ATML3MBTL1 | |
| SCHEMBL5878203 | 0.79 | POLB (0.57) | ALDH1A1MAPTPOLBMMP2MMP9 | |
| SCHEMBL23531478 | 0.71 | KMT2A (0.70) | ALDH1A1ATML3MBTL1 | |
| SCHEMBL18541807 | 0.71 | KMT2A (0.70) | ALDH1A1ATML3MBTL1 | |
| SCHEMBL4188026 | 0.71 | MMP2 (0.85) | ALDH1A1MAPTPOLBMMP2MMP9 | |
| SCHEMBL697591 | 0.71 | MMP2 (0.85) | ALDH1A1MAPTPOLBMMP2MMP9 | |
| SCHEMBL697592 | 0.71 | MMP2 (0.85) | ALDH1A1MAPTPOLBMMP2MMP9 | |
| SCHEMBL28130536 | 0.71 | KMT2A (0.70) | ALDH1A1ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094911-B2 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-22 | — | — | US | disclosed |
| EP-1140809-B1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| US-20040030132-A1 | New biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| US-6677360-B2 | TREATMENT AND PROPHYLAXIS OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOPOROSIS AND EYE DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| US-6420396-B1 | TREATMENT OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOLYTIC DISORDERS, OPHTHALMIC DISORDERS, AND THEIR USE AS INTEGRIN ANTAGONISTS. INHIBITING ANGIOGENESIS | BEIERSDORF AG (DE) | 2002-07-16 | — | — | US | disclosed |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| EP-1140809-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035864-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030132-A1 | New biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB2, ITGB1, ITGB3 | ALDH1A1 753/4885MAPT 4494/4885RXFP1 555/4885 |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB1, ITGB2, ITGB3 | ALDH1A1 635/4885MAPT 4567/4885RXFP1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.